hsa-mir-581: Hsa-mir-581 is a miRNA that has been identified in various studies and is associated with different types of cancer [PMC3917617]. It has been found to be a risky miRNA in Proneural-G-CIMP and Proneural-non G-CIMP subtype GBM, along with other miRNAs [PMC3917617]. Hsa-mir-581 has also been proposed to have an unexpected role as an inhibitor of proliferation of colon cancer cells [PMC4035288]. In G3, hsa-mir-581 is down-regulated, suggesting a possible relation between this miRNA and cancer [PMC4035288]. Hsa-mir-581 has been identified as a ceRNA that binds to multiple miRNAs, including hsa-miR-1200, hsa-miR-1205, hsa-miR-1248, and others [PMC8351580]. In pancreatic ductal adenocarcinoma (PDAC) tissues, hsa-mir-581 is differentially expressed compared to adjacent normal controls [PMC5649611]. It has also been found to promote the expression of hepatitis B virus surface antigen in hepatocellular carcinoma cells by targeting Dicer and EDEM1 [PMC8213537]. Hsa-mir-581 has been predicted to interact with other miRNAs such as hsa-miR-23b-5p and hsa-miR-93-3p [PMC6115511][PMC4900729][PMC4900729]. Additionally, it is inversely correlated with the neutrophil percentage in bronchoalveolar lavage fluid (BALF) samples [PMC6958500]. Hsa-mir-581 was selected as one of the representative miRNAs for validation using RT-qPCR assays in different studies [PMC5865992][PMC5865992][PMC7595675][PMC8305867][PMC7906134].